» Articles » PMID: 23428230

Determinants and Associated Factors Influencing Medication Adherence and Persistence to Oral Anticancer Drugs: a Systematic Review

Overview
Publisher Elsevier
Specialty Oncology
Date 2013 Feb 23
PMID 23428230
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: The use of oral anticancer drugs has increased in modern oncology treatment. The move from intravenous treatments towards oral anticancer drugs has increased the patients' own responsibility to take oral anticancer drugs as being prescribed. High rates of non-adherence to oral anticancer drugs have been reported. A systematic literature review was conducted to gain insight into determinants and associated factors of non-adherence and non-persistence in patients taking oral anticancer therapy.

Review Methods: PubMed, Cochrane, Web of Science and Cinahl were systematically searched for studies focusing on determinants and associated factors of medication non-adherence and non-persistence to oral anticancer drugs. The methodological quality of the included studies was assessed by two independent reviewers. No studies were excluded based on the quality assessment.

Results: Twenty-five studies were included and systematically reviewed. The quality of the studies was moderate. Associated factors influencing medication non-adherence and non-persistence to oral anticancer drugs are multifactorial and interrelated. Older and younger age, and the influence of therapy related side effects were found to be predominant factors.

Conclusion: Non-adherence and non-persistence to oral anticancer drug therapy are complex phenomena. More qualitative research is needed to facilitate the development of patient tailored complex interventions by exploring patients' needs and underlying processes influencing medication non-adherence and non-persistence to oral anticancer drugs.

Citing Articles

Association of medication adherence with treatment preferences: incentivizing truthful self-reporting.

Oedingen C, van Gestel R, Huls S, Granic G, de Bekker-Grob E, Veldwijk J Eur J Health Econ. 2025; .

PMID: 40075020 DOI: 10.1007/s10198-025-01760-z.


The effect of healthcare professional-implemented interventions on adherence to oral targeted therapy in patients with cancer: a systematic review and meta-analysis.

Angus F, Liao W, Adekoya V, Chen L Support Care Cancer. 2025; 33(2):110.

PMID: 39820769 PMC: 11739221. DOI: 10.1007/s00520-024-09136-4.


Impact of Patient Personality on Adherence to Oral Anticancer Medications: An Opportunity?.

Jafari M, Shahverdian A, Sadigh G, Van Etten R JMIR Cancer. 2024; 10:e57199.

PMID: 39475848 PMC: 11561440. DOI: 10.2196/57199.


Pharmacist-facilitated Patient Reported Outcome Measure (PROM) monitoring: developing an EHR SmartForm© to monitor side effects of oral oncolytics during routine telehealth encounters.

Stover A, Liang D, Mueller D, Kurtzman R, Ikemeh C, Canter C Qual Life Res. 2024; 34(1):201-217.

PMID: 39404983 PMC: 11802710. DOI: 10.1007/s11136-024-03789-8.


Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report.

Thomson A, Gunn L, Victor D, Adamson E, Thakrar K Res Rep Urol. 2024; 16:245-252.

PMID: 39399307 PMC: 11471072. DOI: 10.2147/RRU.S485238.